Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100,095 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.
Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Danysh HE, et al. Among authors: li l. Drug Saf. 2023 Feb;46(2):175-193. doi: 10.1007/s40264-022-01262-4. Epub 2022 Dec 30. Drug Saf. 2023. PMID: 36583828 Free PMC article.
Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data.
Beachler DC, Taylor DH, Anthony MS, Yin R, Li L, Saltus CW, Li L, Shaunik A, Walsh KE, Rothman KJ, Johannes CB, Aroda VR, Carr W, Goldberg P, Accardi A, O'Shura JS, Sharma K, Juhaeri J, Lanes S, Wu C. Beachler DC, et al. Among authors: li l. Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):918-926. doi: 10.1002/pds.5257. Epub 2021 May 5. Pharmacoepidemiol Drug Saf. 2021. PMID: 33899314
Response to letter to the editor regarding "Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data".
Beachler DC, Taylor DH, Anthony MS, Yin R, Li L, Saltus CW, Li L, Shaunik A, Walsh KE, Rothman KJ, Johannes CB, Aroda VR, Carr W, Goldberg P, Accardi A, O'Shura JS, Sharma K, Juhaeri J, Lanes S, Wu C. Beachler DC, et al. Among authors: li l. Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):110-111. doi: 10.1002/pds.5376. Epub 2021 Oct 27. Pharmacoepidemiol Drug Saf. 2022. PMID: 34687257 No abstract available.
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.
Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Johannes CB, et al. Among authors: li l. Drug Saf. 2023 Feb;46(2):157-174. doi: 10.1007/s40264-022-01263-3. Epub 2022 Dec 17. Drug Saf. 2023. PMID: 36528670 Free PMC article.
Evidence of h_{b}(2P)→ϒ(1S)η Decay and Search for h_{b}(1P,2P)→ϒ(1S)π^{0} with the Belle Detector.
Kovalenko E, Adachi I, Aihara H, Asner DM, Aushev T, Ayad R, Babu V, Banerjee S, Belous K, Bennett J, Bessner M, Bilka T, Biswas D, Bobrov A, Bodrov D, Bondar A, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Campajola M, Chang MC, Cheon BG, Chilikin K, Cho HE, Cho K, Cho SJ, Choi SK, Choi Y, Choudhury S, Dash N, De Nardo G, De Pietro G, Dhamija R, Di Capua F, Doležal Z, Dong TV, Dubey S, Ecker P, Epifanov D, Ferlewicz D, Fulsom BG, Garg R, Gaur V, Garmash A, Giri A, Goldenzweig P, Graziani E, Gu T, Guan Y, Gudkova K, Hadjivasiliou C, Hara T, Hayasaka K, Hazra S, Hou WS, Hsu CL, Inami K, Ipsita N, Ishikawa A, Itoh R, Iwasaki M, Jacobs WW, Jin Y, Kawasaki T, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kinoshita K, Kodyš P, Korobov A, Korpar S, Križan P, Krokovny P, Kuhr T, Kumar R, Kumara K, Kuzmin A, Kwon YJ, Lai YT, Lam T, Levit D, Li LK, Li Gioi L, Libby J, Liventsev D, Ma Y, Martini A, Masuda M, Matsuda T, Matvienko D, Meier F, Merola M, Miyabayashi K, Mizuk R, Mohanty GB, Mussa R, Nakamura I, Nakao M, Natkaniec Z, Natochii A, Nayak L, Nayak M, Niiyama M, Nishida S, Ogawa S, Ono H, Pakhlova G, Pardi S, Park J, Park SH, Passeri A, Patra S, Paul S, Pedlar TK, Pestot… See abstract for full author list ➔ Kovalenko E, et al. Among authors: li lk. Phys Rev Lett. 2024 Dec 31;133(26):261901. doi: 10.1103/PhysRevLett.133.261901. Phys Rev Lett. 2024. PMID: 39879008
Precise Measurement of the e^{+}e^{-}→D_{s}^{+}D_{s}^{-} Cross Section at Center-of-Mass Energies from Threshold to 4.95 GeV.
Ablikim M, Achasov MN, Adlarson P, Afedulidis O, Ai XC, Aliberti R, Amoroso A, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Bao HR, Batozskaya V, Begzsuren K, Berger N, Berlowski M, Bertani M, Bettoni D, Bianchi F, Bianco E, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Che GR, Chelkov G, Chen C, Chen CH, Chen C, Chen G, Chen HS, Chen HY, Chen ML, Chen SJ, Chen SL, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Chen ZY, Choi SK, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng CQ, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du MC, Du SX, Duan YY, Duan ZH, Egorov P, Fan YH, Fang J, Fang J, Fang SS, Fang WX, Fang Y, Fang YQ, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Feng YT, Fritsch M, Fu CD, Fu JL, Fu YW, Gao H, Gao XB, Gao YN, Gao Y, Garbolino S, Garzia I, Ge L, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo MJ, Guo RP, Guo YP, Guskov A, Gutierrez J, Han KL, Han TT, Hanisch… See abstract for full author list ➔ Ablikim M, et al. Among authors: li lk, li lj, li l. Phys Rev Lett. 2024 Dec 31;133(26):261902. doi: 10.1103/PhysRevLett.133.261902. Phys Rev Lett. 2024. PMID: 39879000
100,095 results
You have reached the last available page of results. Please see the User Guide for more information.